Clinical trials: Prostatic Biopsy
- Condition Prostatic Biopsy
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Prostate Cancer, Urine
Investigation of Urinary Biomarkers for the Detection of Prostate Cancer
The aim of this study is to investigate and possibly validate urinary biomarkers for prostate cancer. During this study the focus will be on aberrations of selected genes as prognostic or predictive value has been shown for these…
- Conditions
- Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP2 (NCT05454371)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- Novosanis NV
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Cancer of the Prostate
Decision Impact Trial of the ExoDx Prostate (IntelliScore)
The purpose of this research study is to investigate the utility of a validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy.
- Trial name
- NCT03235687
- Testing
- ExoDx Prostate (IntelliScore)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Prostate Cancer
Prospective Validation of Prostate Biomarkers for Repeat Biopsy
Target enrollment is 1000 prospectively enrolled subjects with an initial negative biopsy scheduled for repeat biopsy. Subjects must have had their negative index prostate biopsy procedure within 30 months of being scheduled for…
- Trial name
- PRIORITY (NCT03082274)
- Testing
- ConfirmMDx, SelectMDx
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- MDx Health
Prostate Cancer
Prostate Biopsy Access Needle & Needle Guide Feasibility Study
The objective of the study is to assess the design features of a modified stainless steel access needle (single use disposable) in a clinical setting and a disposable, single use, custom-made, polymer needle guide used in…
- Trial name
- STABLE (NCT02828839)
- Testing
- Access needle
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Perineologic
Prostate Cancer (Adenocarcinoma), Prostate Biopsy
RegisterPROS - A Registry for Prostate Cancers
Prostate cancers are derived from epithelial cells in the prostate gland. Treatment options include surgery, medical (androgen signaling targeted and chemotherapy) and radiation therapy including radioligand therapy (RLT).
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Biopsy, Prostatectomy, Radioligand
- Trial name
- RegisterPROS (NCT06872619)
- Testing
- PROSTest
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Wren Laboratories LLC
Brest Cancer, Lung Cancer (NSCLC)
The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients.
- Conditions
- Brest Cancer, Lung Cancer (NSCLC), Pancreatic Cancer, Adult, Prostate Cancers
- Trial name
- CCANED-CIPHER (NCT06717295)
- Testing
- DiNanoQ: A multi-cancer early detection (MCED) blood test, DiNanoTrack: Therapeutic Response Monitoring Blood Test
- Where
- 4 sites in Argentina, Nigeria and 1 more
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Javier Toledo
Breast Cancer, Prostate Cancer
Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications
The aim of this study is to evaluate and optimize protocols for the isolation and analysis of analytes in urine (cell-free nucleic acids, extracellular vesicles and proteins).
- Conditions
- Breast Cancer, Prostate Cancer, Urine, Liquid Biopsy
- Trial name
- URODETECT-WP1 (NCT05453604)
- Testing
- Colli-Pee UAS devices
- Where
- Belgium
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Novosanis NV
Prostate Cancer
ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting
The study is designed to confirm the performance of the ExoDx Prostate test in prior negative biopsy patients now presenting for a repeat prostate biopsy.
- Trial name
- NCT04357717
- Testing
- ExoDx Prostate
- Where
- 2 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
Cancer of Prostate
Clinical Evaluation of the 'ExoDx Prostate IntelliScore' (EPI)
The purpose of this research study is investigate a new and validated urine test which predicts the likelihood of high grade prostate cancer on an initial prostate biopsy The current protocol has two objectives; one is to further…
- Trial name
- NCT03031418
- Testing
- ExoDx Prostate Intelliscore
- Where
- 18 sites in United States
- Volunteers
- 532 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
PCA, Prostate Cancer
PSMA PET Combined With MRI for the Detection of PCa
This is an open label, longitudinal Phase 3 study of prostate specific membrane antigen (PSMA) positron emission tomography (PET) combined with magnetic resonance imaging (MRI) compared to standard of care (SOC) for the detection…
- Conditions
- PCA, Prostate Cancer, Prostatic Neoplasm, PSMA PET
- Trial name
- BiPASS (NCT07052214)
- Testing
- 68Ga-PSMA-11
- Where
- 18 sites in United States, Australia
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Prostatic Neoplasms
Analysis of Cell-free DNA (cfDNA) in Men With Elevated PSA Levels
This is a multi-centre prospective study in which blood samples will be taken from 1500 male patients aged between 21-80 scheduled for prostate biopsy.
- Trial name
- NCT02771769
- Testing
- blood draw
- Where
- 2 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Chronix Biomedical Corporation